What to Expect When Starting CGRP Migraine Prevention

Understanding CGRP migraine prevention what to expect is one of the most practical things you can do before your first dose. The experience varies more than most patients anticipate, and going in with realistic timelines and a plan for what to track makes the whole process easier to evaluate. This guide covers the first few months on a CGRP preventive, the signals worth paying attention to, and the data your clinician will want when it comes time to assess your response.

How CGRP Prevention Works (The Short Version)

CGRP stands for calcitonin gene-related peptide, a protein that plays a central role in migraine attacks. During an attack, CGRP levels rise sharply in the blood and are associated with the pain and inflammation that define the episode. Preventive therapies in this class work by blocking either CGRP itself or its receptor, reducing how often the migraine cascade gets triggered in the first place.

For a fuller explanation of the underlying biology, see what is CGRP. The key point for practical purposes: this is a mechanism-targeted approach rather than a general pain suppressor, which is why the timeline and response pattern differ from older preventives.

What to Expect in the First Three Months

The most common mistake patients make is evaluating too soon or not tracking carefully enough to evaluate at all.

Month One

Some people notice a reduction in attack frequency or severity within the first four weeks. Others feel no change whatsoever. Both experiences are normal at this stage, and neither reliably predicts the three-month outcome.

What matters most in month one is not how you feel but whether you are collecting data consistently. Each migraine day, severity score, and acute medication use logged now becomes the comparison point for everything that follows.

Side effects, if they appear, are often most noticeable early on. Injection-site reactions are common with the self-administered forms. Fatigue, mild dizziness, or constipation are reported by some patients. Most early side effects settle over the first few weeks, but any side effect that concerns you warrants a call to your prescriber. Only your clinician can evaluate whether continuing, adjusting, or stopping treatment is appropriate.

Month Two

By month two, the signal in your data starts to become readable. If you have been logging daily, you can begin to see whether your migraine day count is trending down from baseline.

A useful check at the end of month two: compare your migraine days for the past four weeks to the monthly average you recorded before starting. Any reduction is worth noting; a 30 to 50 percent drop is an encouraging sign.

Acute medication use is a second signal to watch here. If your rescue medication days are decreasing alongside migraine days, that reinforces that the preventive is having a real effect. Unchanged acute medication use despite a lower migraine day count might suggest the migraine definition you are using needs to be discussed with your clinician.

Month Three

Three months is the standard minimum evaluation point. Most clinicians and payers use a three-month average to judge response because it smooths out the month-to-month variability that can mislead a single-month comparison.

At the three-month mark, your clinician will typically want to know:

• Your average monthly migraine days before starting versus the past three months
• Any change in attack severity or duration
• How often you have needed acute medication
• Whether your functional disability has improved

This is the data a formal disability questionnaire like MIDAS is designed to capture. See the MIDAS calculator to score your current level and compare it to where you were before treatment.

What Counts as a Meaningful Response

The benchmark used in clinical trials is a 50 percent or greater reduction in monthly migraine days. Insurance plans often use this same threshold for prior authorization renewal.

But "meaningful" is broader than that single number. If your migraine days dropped by 35 percent and your attacks are shorter and less severe, your functional disability may have improved dramatically even if the headline count does not clear 50 percent. Migraine-related disability is what you are ultimately trying to reduce, so track severity and impact alongside frequency.

Use the migraine reduction calculator to see how your current monthly count compares to your baseline as a percentage change. This number is often exactly what a prior authorization reviewer or clinician asks for.

What to Track and Why It Matters

Consistent daily logging is the foundation of evaluating any preventive. The specific data points that matter most:

For a complete list of what to record and how, see what to log in a migraine diary.

The baseline you establish before treatment is as important as the tracking you do during treatment. If you have already started a CGRP preventive without a pre-treatment baseline, start logging now. Your data from this point forward still gives you a before-and-after comparison once several months have accumulated.

How This Connects to Prior Authorization Renewal

CGRP preventives typically require prior authorization, and renewal is not automatic. Insurers generally ask for documentation that the treatment is working, usually framed as a reduction in monthly migraine days from baseline along with current disability scores.

The data you collect during treatment is the evidence that renewal depends on. Patients who log consistently have what they need; patients who relied on memory typically do not. The CGRP prior authorization renewal guide explains what documentation is usually required and how to prepare it.

Questions to Bring to Your Clinician

When you reach the three-month evaluation point, going in with organized data and prepared questions makes the visit more productive. Consider asking:

• Based on my tracking data, does my response meet the threshold to continue this treatment?
• If I am a partial responder, are there adjustments that might improve my result?
• Should I continue for another three months to see if the response improves?
• Are my side effects within the expected range, or do they warrant reconsidering this approach?

Only your clinician can make changes to your treatment, including starting, stopping, or adjusting dosing. Come to the appointment with data, not just impressions.

Building the Picture Over Time

CGRP migraine prevention what to expect is not a single answer but a process that unfolds over months. The patients who get the most useful information from the experience are the ones who started logging before their first dose, kept logging consistently through the trial period, and arrived at the evaluation appointment with a clear before-and-after comparison.

Understanding how to measure CGRP progress in concrete numbers helps you have a more grounded conversation with your prescriber and, when renewal time comes, with your insurer.

Consistent daily logging in a structured app turns the data you collect into the renewal report your clinician and insurer need, including baseline averages, monthly migraine day counts, percentage reduction, and disability scores formatted for a prior authorization submission. If you have questions about starting, stopping, or changing any treatment, consult your doctor before making any changes.